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peptides, a new type of drug-delivery vesicle has been developed. The preparation, based on sodium dodecyl
sulfate (SDS) and β-cyclodextrin (β-CD) embedded in chitosan gel, was used to successfully deliver the model
drug-insulin. The self-assembled SDS/β-CD vesicles were prepared and characterized by particle size, zeta
potential, appearance, microscopic morphology and entrapment efﬁciency. In addition, both the interaction of
insulin with vesicles and the stability of insulin loaded in vesicles in the presence of pepsin were investigated.
The vesicles were crosslinked into thermo-sensitive chitosan/β-glycerol phosphate solution for an in-situ gel to
enhance the dilution stability. The in vitro release characteristics of insulin from gels in media at different pH
values were investigated. The insulin loaded vesicles–chitosan hydrogel (IVG) improved the dilution stability
of the vesicles and provided pH-selective sustained release compared with insulin solution–chitosan hydrogel
(ISG). In vitro, IVG exhibited slow release in acidic solution and relatively quick release in neutral solutions to
provide drug efﬁcacy. In simulated digestive ﬂuid, IVG showed better sustained release and insulin protection
properties compared with ISG. Thus IVG might improve the stability of insulin during its transport in vivo and
contribute to the bioavailability and therapeutic effect of insulin.
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Insulin delivery with pH-selective release 3451. Introduction
The ordered assemblies formatted by some amphiphilic molecules
exhibiting bilayer structures, such as natural or synthetic surfac-
tants, is a well-known phenomenon. In general, amphiphilic
molecules participating in self-assembling can be natural or
synthetic surfactants which result in two very different structures
deﬁned as liposomes1–3 and vesicles, respectively. They have been
widely used in the delivery of small molecule drugs4–6 and
macromolecular protein drugs3,7,8. Vesicular carriers offer the
following advantages: (i) they facilitate drug absorption across
the bilayer membrane, (ii) they can improve drug stability by
protecting it from biological environment, resulting in better
bioavailability and therapeutic efﬁcacy, (iii) they can regulate
drug delivery rate thereby promoting sustained release. The non-
ionic surfactant vesicles (named niosomes) are composed of non-
ionic surfactant and cholesterol or its derivatives. Niosomes have
been widely studied as one type of synthetic surfactant vesicle9–11.
In our research, we employed another relatively new type of
synthetic surfactant vesicles consisting of anionic surfactant and
cyclodextrins (CDs).
CDs have been widely used in pharmaceutical formula-
tions12,13 and have undergone continuous development since
they were ﬁrst reported by Villiers in 189114. CDs consist of
identical α-D-glucopyranose units linked by α-1,4 glycosidic
bonds to form a round macromolecule. CD formulations are
shaped as hollow, truncated cones rather than perfect cylinders
due to the chair conformation of the glucopyranose units. The
bigger and smaller edges of the cone are referenced as the “head”
and “tail”, respectively. The secondary hydroxyl groups form at
the head, whereas the primary hydroxyl groups are seen at the
tail15. The most common CDs containing 6, 7 and 8 α-D-
glucopyranose units are called α-CD, β-CD and γ-CD, respec-
tively. It has long been considered that the addition of CDs
disfavors the self-assembly of surfactants in dilute solutions since
the hydrophobic effect is destroyed upon the formation of the
hydrophiphilic CD/surfactant inclusion complex16. However,
some researchers have reported the nonamphiphilic self-
assembly behavior of hydrophilic sodium dodecyl sulfate/β-CD
(SDS/β-CD) complexes in water, which did not rely on theFigure 1 Schematic diagram of the formation ohydrophobic effect. As reported, annular-ring tubes (i.e., multi-
lamellar tubes) formed in SDS/β-CD aqueous solution from
concentration of 6%–25%, w/v (total mass concentration of
SDS and β-CD). Lamellar structures were found when the
concentration range extended to 25%–50%, w/v and vesicles
were revealed from 4% to 6%, w/v17. In addition, vesicles and
microtubes can reversibly interchange upon temperature alterna-
tion18. Herein, we only focused on the vesicle preparations and
investigated the properties of vesicles used as carriers of
macromolecular drugs.
As is known, insulin monotherapy can be used as early
treatment for patients with type 2 diabetes mellitus or as an
alternative or add-on in patients with inadequate glycemic control
despite treatment with oral antidiabetic agents, diet and exercise
therapy19. Because of the popularity of insulin delivery in
pharmaceutical research7,8,20–24, insulin was selected as the model
drug delivered by SDS/β-CD vesicles in this report.
The fabrication mechanism of insulin-loaded vesicles is
shown in Fig. 1. The hydrophobic carbon chain of SDS was
wrapped into the β-CD cavity forming host-guest molecules
complex of β-CD and SDS in a 2:1 molar ratio in the solution.
The complex formed lamellar structure at high concentrations
(25%–50%, w/v) but self-assembled into vesicles at lower
concentrations (4%–6%, w/v) when incubated under suitable
conditions17. The vesicles showed a closed hollow spherical
structure by bending of the bilayer membrane. The insulin
molecules were positively charged in hydrochloric acid solution
(pH 2.6) with an isoelectric point of 5.35–5.45, which not only
helps the drug into the interior cavity of vesicles, but also
possibly combines with the negatively charged SDS through
electrostatic force, thereby improving the afﬁnity of the drug for
the carrier. Since the SDS/β-CD system only exists in vesicular
form in a narrow scope of concentration, the vesicles were
crosslinked into thermo-sensitive chitosan/β-glycerol phosphate
(β-GP) solution to prepare in-situ gel in order to further improve
the stability of the vesicular system25–27.
In summary, the purposes of this study were: (i) to fabricate
of a new type of protein/peptide-loaded vesicles based on SDS
and β-CD, (ii) to study insulin interaction with the vesicles and
(iii) to investigate the in vitro release characteristics of insulinf SDS/β-CD vesicles and loading of insulin.
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selectivity.2. Materials and methods
2.1. Materials
Insulin was purchased from Wanbang Jinqiao Pharmaceutical Co.,
Ltd. (Xuzhou, Jiangsu, China). β-CD was obtained from Anhui
Sunhere pharmaceutical excipients Co., Ltd. (Anhui, China). SDS
was purchased from Sigma-Aldrich Company (St. Louis, MO,
USA). Pepsin (enzyme activity Z1200 U/g), trypsin (enzyme
activity Z2500 U/mg) and β-GP (disodium salt pentahydrate)
were obtained from Sinopharm Chemical Reagent Co., Ltd.
(Shanghai, China). Chitosan (molecular weight about 1000 kD)
was purchased from Zhejiang Golden-Shell biological chemical
Co., Ltd. (Taizhou, Zhejiang, China). Acetonitrile (HPLC grade)
was obtained from Merck Co., Ltd. (Darmstadt, Germany). Other
reagents were of analytical grade. Water was puriﬁed by Milli-Q
system (Millipore, Bedford, MA, USA).
2.2. Preparation of vesicles
Two methods of preparation were employed, a dilution method and a
direct preparation method. For the former, desired amounts of β-CD,
SDS and water were weighed into a small beaker to obtain a constant
SDS/β-CD molar ratio (2:1). The sample was then heated to 60 1C in
water bath to obtain an isotropic solution as concentrated sample, the
total concentration of β-CD and SDS in this solution was 25%, w/v.
The concentrated solution was diluted 5 times with hydrochloric acid
solution (pH 2.6) to prepare low concentration samples. The
solutions were incubated at 25 1C for over 24 h to allow the self-
assembly of SDS/β-CD blank vesicles.
For the direct preparation method, desired amounts of β-CD and
SDS were weighed and transferred with hydrochloric acid solution
(pH 2.6) into a small beaker to obtain a constant SDS/β-CD molar
ratio (2:1). Then the sample was heated to 60 1C in water bath to
obtain an isotropic solution. The total concentration of β-CD and
SDS in this solution was 5%, w/v. The solutions were then
incubated at 25 1C for over 24 h to allow self-assembly of SDS/β-
CD blank vesicles.
Insulin-loaded vesicles were prepared by the same procedure,
but insulin was ﬁrstly dissolved in hydrochloric acid solution (pH
2.6). All samples were stored at 4 1C for further use.
2.3. Characterization of vesicles
2.3.1. Particle size and zeta potential
The size and zeta potential of vesicles were measured by a
dynamic light scattering (DLS) method by use of the Malvern
Zetasizer Nano ZS 90 instrument (Malvern Instruments Ltd.,
Worcestershire, UK) at 25 1C. The scattering angle was ﬁxed at
901. The size distribution results were described as percentage of
intensity. The polydispersity index (PDI) value was determined as
a measurement of the breadth of the size distribution. The PDI
value (lower than 0.3) and count rate (ranged 100–300 kcps)
indicated a homogenous and monodisperse population. Zeta
potential was measured by the principle of Laser Doppler
electrophoresis, and higher potential indicated better stability of
the system. The assays were performed in triplicate.2.3.2. Macroscopic appearance
The macroscopic appearance of the vesicles was directly observed
by the naked eye.
2.4. Entrapment efﬁciency
The entrapment efﬁciency (EE, %) of insulin in vesicles was
determined by centrifugation to separate free insulin from
entrapped drug. Brieﬂy, 0.5 mL of insulin-loaded vesicles suspen-
sion was introduced into a clean tube and centrifuged at
12,000 rpm for 5 min. The precipitate was collected and diluted
with sodium hydroxide solution (0.01 mol/L) in order to fully
dissolve the precipitate. The solution was again centrifuged at
12,000 rpm for 5 min and the concentration of insulin in the
supernatant was assayed by HPLC as described below. EE (%)
was then calculated using Eq. (1).
EE %ð Þ ¼Wd
W t
 100 ð1Þ
where Wt and Wd were the amounts of insulin in total and loaded
in the vesicles respectively.
2.5. Interaction of insulin with vesicles
Desired amount of insulin was added into suspension of blank
vesicles, the amount of insulin was equal to that of insulin loaded
vesicles. Then, the mixed system was incubated at 25 1C for
30 min to make sure that the insulin fully interacted with the
vesicles. The particle size and zeta potential was measured by the
same parameters as explained above.
2.6. In vitro pepsin degradation
The stability of the insulin in the presence of pepsin was
investigated in order to validate whether the vesicles could protect
insulin from the degradation. Typical incubations were described
as follows. Pepsin solution (600 μg/mL, 0.72 U/mL), insulin
solution, insulin loaded vesicles and the mixture of insulin and
blank vesicles were preheated in a water bath at 37 1C for 15 min,
after which 50 μL pepsin solution and 950 μL samples were
introduced into clean tubes and vortexed quickly and placed in a
water bath at 37 1C. Incubations were stopped at intervals of 0, 5,
20, 60, 90 and 120 min by withdrawing 50 μL incubated solution
to a new plastic tube with addition of 100 μL ice-bathed tris buffer
(pH 8.0, 1 mmol/L CaCl2 included)
28. The tubes were immediately
vortexed and placed on ice for 30 min and centrifuged at
12,000 rpm for 5 min. The concentration of insulin in supernatant
was analyzed by HPLC as described below. The assays were
performed in triplicate.
2.7. Preparation of thermo-sensitive crosslinked chitosan
solutions
One mL of 65% (w/v) β-GP (in deionized water) solution was
added to 3 mL of 3% (w/v) chitosan solution (in 1%, v/v, acetic
acid) drop-wise, stirring continuously over ice bath. The ﬁnal
solution was stirred for additional 10 min to ensure complete
mixing. Vesicles were embedded into the chitosan network by
adding vesicles into the prepared CS-β-GP solution, mixing
thoroughly at 25 1C. The resulting solution was allowed to
facilitate crosslinking to completely become a gel in an incubator
Table 1 The particle size, PDI and zeta potential of vesicles prepared by different methods (n¼3).
Sample Preparation method Size (nm) PDI Zeta potential (mV)
Blank vesicles Dilution 1421784 0.29470.041 49.572.3
Blank vesicles Direct preparation 16297251 0.82370.146 49.871.3
Insulin-loaded vesicles Dilution 871742 0.18770.058 39.472.0
Figure 2 Particle size distributions of blank vesicles (a) and insulin
loaded vesicles (b).
Insulin delivery with pH-selective release 347at 37 1C for 1 h. The resultant IVG was used immediately for
drug-release experiments. Insulin solution–chitosan hydrogel
(ISG) was prepared by the same procedure as a reference, simply
replacing insulin vesicles with insulin solution.
2.8. In vitro drug release studies
2.8.1. Without enzymes
The gels were placed in the containers containing 50 mL of
phosphate buffer solution (PBS, pH 2.5, 6.8 or 7.4) or citric acid–
disodium hydrogen phosphate buffer solution (pH 4.0) at
3771 1C with mild stirring. At designated time points (15,
30 min, 1, 2, 4, 8, 10 and 24 h), 0.5 mL of the release media
was withdrawn and the same volume of fresh media incubated at
3771 1C was added into the containers. All the samples were
centrifuged at 12,000 rpm for 5 min and the concentration of
insulin in supernatant was analyzed by HPLC as described below.
The assays were duplicated in triplicate.
2.8.2. With enzymes
Simulated gastric ﬂuid (SGF) and simulated intestinal ﬂuid (SIF)
with enzymes were used to mimic the gastrointestinal conditions
in vivo. SGF consisted of 2.0 g NaCl in 1 L pure water with pH of
1.2070.02 adjusted by hydrochloric acid, then pepsin was added
(3.2 mg/mL) and the solution was sufﬁciently stirred. SIF was
composed of a buffer (50 mmol/L Tris, 50 mmol/L maleate,
150 mmol/L NaCl, 5 mmol/L CaCl2), bile salts (5 mmol/L cho-
lates) and phosphatidylcholine (1.25 mmol/L soybean lecithin)29.
The ﬁnal pH was adjusted to 7.5070.02, then trypsin was added
(10 mg/mL) and the solution was sufﬁciently stirred.
The gels were placed in the containers and 50 mL of SGF or SIF
was added at 3771 1C with mild stirring. The dissolution medium
was carefully poured out after 1 h, the remaining portion of the gel
was dissolved with an adequate volume of dilute hydrochloric acid
solution (pH 1.2, without pepsin) under 37 1C with rapid stirring.
All the samples were centrifuged at 12,000 rpm for 5 min. The
concentration of insulin in supernatant was analyzed by HPLC as
described below. The assays were performed in triplicate.
2.9. Determination of insulin
Insulin was assayed by a reversed-phase HPLC–UV method. The
HPLC system (1260 Series, Agilent Technologies, USA) was
composed of a quaternary pump, a degasser, an autosampler, a
column heater and a tunable ultraviolet detector. The separation
was achieved on the Vydac C18 analytical column (150 mm 4.6
mm i.d., 5 μm; Grace, USA) maintained at 35 1C. The mobile phase
was composed of acetonitrile and 0.1% triﬂuoroacetic acid solution
using gradient elution and the ﬂow rate was set to 1.0 mL/min. The
detection wavelength of the detector was set at 214 nm. The HPLC
method was of good speciﬁcity and accuracy, and the linear range
was 5–400 μg/mL.3. Results and discussion
3.1. Preparation method, size and zeta potential of vesicles
The vesicles prepared by two methods were obviously different
(Table 1). The standard deviation for particle size of the direct
preparation method was signiﬁcantly greater than those obtained
from the dilution method, although mean diameters were similar.
In addition, PDI values varied remarkably between the two
methods. The PDI value obtained from the direct method was
higher than 0.70, indicating that the system was not uniform and
had poor dispersibility. On the other hand, the system prepared by
the dilution method was homogeneous and well-dispersed with
PDI value of 0.30. Thus, the dilution method seemed to favor
formation of cyclodextrin inclusion complexes at the higher
reagents concentrations, thereby promoting self-assembly into
vesicles after dilution. No large differences in zeta potential were
observed between samples prepared by two methods, since the
amount of negatively charged SDS remained unchanged.
Since the preparation method showed signiﬁcant impact on the
particle size but almost no effect on zeta potential, the dilution
method was selected for the preparation of vesicles. This method
yielded narrowly-distributed particle sizes for blank and insulin-
loaded vesicles (Fig. 2).3.2. Macroscopic appearance
Blank and insulin-loaded vesicles were observed macroscopically
(Fig. 3). For the 5% (w/v) system of SDS/β-CD, the suspension of
blank vesicles was of low turbidity at 25 1C; however, the turbidity
of insulin-loaded vesicles was higher at the same temperature,
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the components of vesicles.3.3. EE
The EE of insulin loaded SDS/β-CD vesicles prepared by dilution
method was 87.6278.56% (n¼6). For comparison, the entrap-
ment efﬁciency of vesicles obtained from direct preparation
method was measured to be 80.5876.79% (n¼6). The drug-
loading efﬁciency was 1.4770.14% (n¼6) for the dilution
method and 1.3770.11% (n¼6) for the direct preparation method.
Thus, the drug-loading efﬁciencies of the two methods were
similar. Because of the possible electrostatic interactions in the
system, the interactions of the drug and the carrier were further
studied as below.3.4. Interaction of insulin with vesicles
The insulin could be located in three possible ways in the vesicles,
namely, being adsorbed on the vesicle bilayer membrane, encap-
sulated in the inner cavity of vesicles or both. The insulin-loaded
vesicles showed smaller particle size when compared with blank
vesicles. It was known that insulin was positively charged under
the given conditions (pH 2.6) with an isoelectric point of 5.35–
5.45. The reduction of particle size from 1421784 nm to
871742 nm following insulin loading might be due to the
combination of partial insulin with negatively charged SDS by
an electrostatic force, resulting in the shrinkage of the hollow
vesicles. When insulin was physically mixed with blank vesicles,
the particle size reduced from 1421784 nm to 682718 nm,
indicating that the contractile effect caused by electrostatic
interaction was stronger than that in insulin loaded vesicles. In
other words, the loaded insulin interacted with SDS/β-CD vesicles
not only by electrostatic force, but a part of insulin may also be
wrapped inside the vesicles.
The zeta potential is a sign of the strength of attractive and
repulsive forces between particles. The higher zeta potential
(positive or negative) indicates the greater stability of the system.
In general, if the absolute value of zeta potential was higher than
30 mV, the system could be considered in the stable category. The
zeta potential of the blank and insulin loaded vesicles were about
50 mV and –40 mV, respectively, showing a change of about
10 mV after insulin loading. However, the zeta potential of the
physical mixture was 9.671.1 mV, with a variation valueFigure 3 Macroscopic photos of blank vesicles (a) and insulin-
loaded vesicles (b).between blank vesicles and the physical mixture of nearly
40 mV. These data suggest that only a small fraction of insulin
was combined on the surface of vesicles by electrostatic forces and
that most of the insulin was wrapped in the inner compartment of
the vesicles in the case of insulin-loaded vesicles.
3.5. Stability of the particle size
The physical stabilities of blank and insulin-loaded vesicles were
evaluated by comparing the changes in the mean diameters, during
their storage at 4 1C for over three months (Fig. 4). The particle
sizes for both were not signiﬁcantly changed and remained in
acceptable range of 1420–1590 nm for the blank and 870–970 nm
for the insulin-loaded one. Thus, the vesicles can be stored and
remain stable at 4 1C and for extended periods.
3.6. In vitro pepsin degradation
The in vitro degradation of insulin solutions and insulin-loaded
vesicles were investigated in the presence of pepsin over a period
of 120 min. The remaining percentages of insulin incubated with
pepsin for 1 h were 14.2% and 87.2% for insulin solution and
insulin-loaded vesicles, respectively (Fig. 5a). The signiﬁcant
decline in the insulin percentage/concentration was recorded for
the ﬁrst one hour of degradation process. After incubation with
pepsin for 2 h, 81.0% insulin remained in vesicles. However, the
residual percentage of insulin in solution was only 5.11%. The
data clearly show that the vesicles successfully protected the
insulin from the degradation by pepsin. The degradation of insulin
followed typical ﬁrst order kinetics (Fig. 5b). The ﬁrst-order
kinetic rate constants of solution and the vesicles were
1.61 103 min1 and 2.56 102 min1, respectively. Thus
the half-life of insulin solution was 27.1 min in pepsin solution and
then was prolonged to 432 min for insulin-loaded vesicles.
3.7. In vitro drug release
3.7.1. Without enzymes
The in vitro drug release of insulin-containing gels was studied at
pH 2.5, 4.0, 6.8 and 7.4 (Fig. 6), which simulated the pH proﬁle
from gastric to intestinal conditions. First of all, both ISG and IVG
showed sustained-release characteristics under the all pH condi-
tions, and continuously released insulin for 24 h. MoreFigure 4 Particle sizes of the blank and insulin loaded vesicles
stored at 4 1C (n¼3).
Figure 5 The degradation proﬁles (a) and degradation kinetic curves (b) of insulin solution (♦) and insulin loaded vesicles in pepsin solutions (▲)
(n¼3).
Figure 6 Cumulative release proﬁles of ISG (♦) and IVG (▲) under different pH conditions (n¼3).
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did not vary obviously across pH conditions. In contrast, IVG
showed substantial differences in release at varied pH values. In an
acidic environment, only a small amount of insulin was released
with the remaining amounts protected from acidic environment
and pepsin. In a neutral or weakly alkaline environment, insulin
was quickly released to provide therapeutic effect.
Furthermore, although no signiﬁcant differences in release rates
were observed between ISG and IVG in media of pH 6.8 and pH
7.4 within 10 h, ISG showed slightly slower and sustained release
behavior vs. IVG between 10 and 24 h. The most signiﬁcant
difference observed between ISG and IVG was reﬂected in the
release proﬁle in the acidic environment. In release media of pH2.5 and pH 4.0, IVG demonstrated substantially slower release as
compared with ISG even from the initial period. However, it is
worth mentioning that the gel would begin to dissolve within
30 min under pH conditions lower than pH 2.0. The variation of
cumulative release percentages between IVG and ISG in release
media of pH 2.5, 4.0, 6.8 and 7.4 were 79.9%, 57.9%, 13.4% and
10.2%, respectively. Thus, the differences between insulin release
from IVG and ISG increased with decreasing pH values, indicating
that the presence of vesicles changed the release behavior of
insulin from the gels.
Overall, IVG showed pH-selective release of insulin in vitro,
suggesting the improved stability and bioavailability of insulin
from this formulation in vivo. SDS/β-CD vesicles helped the gel to
Figure 7 CD spectra of free insulin solution, insulin extracted from
the vesicles and insulin isolated from gels.
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chitosan gel was effective to improve the stability of the vesicles
when being diluted.
3.7.2. With enzymes
The release of insulin from gels was studied in SGF and SIF with
digestive enzymes. After release in SGF and SIF for 1 h at 37 1C,
the residual percentage of insulin in IVG and ISG varied
considerably. The percentage of insulin remaining was 13.9% in
IVG, while the content of insulin was undetectable in ISG after
incubation in SGF. In SIF, the residual insulin percentages of IVG
and ISG were 18.3% and 3.00% (Po0.05), respectively. This
shows that IVG exhibits better sustained release and insulin-
protecting properties compared with ISG in simulative digestive
ﬂuid. The gels showed faster release characteristics in the
simulated gastrointestinal environment than that under in vitro
conditions. This phenomenon is probably due to the presence of
digestive enzymes as well as bile salts and phosphatidylcholine.
3.8. Determination of the secondary structure of insulin
Circular dichroism (CD) was employed to characterize the second-
ary structures of insulin in the vesicles and IVG (Fig. 7). The CD
spectra showed that all samples were very similar for typical
features of α-helix structure of proteins with a positive absorption
peak below 200 nm and two negative absorption peaks at 208 and
222 nm, all of similar magnitude. The characteristic peak of the β-
sheet was not obvious at 215–217 nm because of the low insulin
concentrations in the samples. The noise in 190–200 nm range of
insulin isolated from IVG was attributed to the residual impurities or
high concentration of chloride ions in the sample. Thus, the
preparation conditions and the system had little effects on the
conformation and the secondary structure of insulin in carriers.4. Conclusions
In the current study, a novel type of SDS/β-CD vesicles was used
to deliver protein/peptide drug with high encapsulation efﬁciency.
The insulin-loaded vesicles showed excellent physical stability and
protect insulin from proteolytic degradation. In addition, IVG
made from the strategy of “drug-in-vesicles-in-gels” improved the
stability of the vesicles undergoing dilution and provided selective
sustained release at different pH values in vitro when comparedwith ISG. Speciﬁcally, only a small amount of insulin was released
in acidic environments thereby protecting most of the drug from
degradation. Insulin release rates gradually increased with increas-
ing pH values. In neutral and weakly alkaline environments,
insulin was quickly released to provide therapeutic effects. In SGF
and SIF with enzymes, IVG preparations showed better sustained
release and insulin-protecting properties compared with ISG. The
results suggest that the presently-described IVG preparations
might increase the stability and bioavailability of insulin in vivo.References
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